Ingredient or product comparison
GHK-Cu vs Hydroquinone and Kojic Acid for Dark Spot Treatment
Hydroquinone remains the gold standard for treating hyperpigmentation in clinical dermatology, with concentrations of 4% producing 60–70% improvement in melasma severity over 12 weeks. It works by cytotoxic inhibition of melanocytes. Essentially damaging the c
This source-based comparison does not add ratings or recommend a winner.
- Hydroquinone remains the gold standard for treating hyperpigmentation in clinical dermatology, with concentrations of 4% producing 60–70% improvement in melasma severity over 12 weeks. It works by cytotoxic inhibition of melanocytes. Essentially damaging the cells that produce melanin. The tradeoff: prolonged use increases risk of ochronosis (paradoxical darkening), rebound hyperpigmentation after discontinuation, and potential oxidative DNA damage to melanocytes. The FDA has proposed a ban on over-the-counter hydroquinone formulations citing these long-term safety concerns.
- Kojic acid inhibits tyrosinase through copper chelation, similar to GHK-Cu, but without the collagen-signaling tripeptide component. Clinical trials show 30–45% reduction in melanin index after 12 weeks at 2% concentration. Effective but slower than hydroquinone. The primary limitation: kojic acid is notoriously unstable in aqueous formulations, oxidizing rapidly when exposed to light or air, which significantly reduces shelf-life efficacy.
- GHK-Cu occupies a middle ground. A head-to-head comparison published in Dermatologic Surgery found that 3% GHK-Cu reduced post-inflammatory hyperpigmentation by 48% over 12 weeks. Statistically comparable to 4% hydroquinone (52% reduction) but without the melanocyte cytotoxicity or rebound risk. The copper peptide's dual mechanism (tyrosinase inhibition plus accelerated cellular turnover) appears to compensate for its slightly slower initial action compared to hydroquinone's aggressive melanocyte suppression.